Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease

Table 1 Right and left ventricular parameter before and after fingolimod application

	Diagnosed PAH	Pre-FTY	Post-FTY 1 month	3 month follow up	9 month follow up
NYHA	III	II	II	II	II
HR [bpm]	80	77	65	60	68
BP [mmHg]	120/88	130/80	110/90	122/85	125/85
RVESP [mmHg]	90	70	65	n.d.	55
TAPSE [mm]	13	21	n.d.	n.d.	20
Right ventricle hypertrophy	mild	mild	mild	n.d.	mild
LV EF	45%	60%	60%	n.d.	60%
NT-proBNP [pmol/L]	207	17	16	15	11
pH (cap.)	7.46	7.54	7.52	7.47	7.43
PO2 (cap.) [kPa]	12.3	10.1	11.7	10.4	10.4
PCO2 (cap.) [kPa]	3.9	4.6	3.5	4.6	4,72
Respiratory resistance	Normal	Normal	Normal	Normal	Normal
Obstructive ventilation	Normal	Normal	Normal	Normal	Normal
Restrictive ventilation	Normal	Normal	Normal	Normal	Normal
Diffusion respiration	TLCO SB 49%	TLCO SB 51%	TLCO SB 53%	TLCO SB 50%	TLCO SB 49%

FTY, Fingolimod; n.d., not done. Reference values: RVESP: 15–30 mmHg; TAPSE: < 20 mm; LV-EF, left ventricular ejection fraction: 50–70%; NT-proBNP: ≤ 17 pmol/L, pH (capillary): 7.35-7.45; PO2 (capillary), partial pressure of oxygen: 11.1-14.4 kPa; PCO2 (capillary), partial pressure of carbon dioxide: 4.27-6.4 kPa; TLCO SB, transfer coefficient of lung for carbon monoxide: > 60%.

ISSN: 1471-2377